Exosomal hsa_circ_0008925 from Urine Is Related to Chronic Renal Fibrosis

Yuhan Cao,1,2,3 Yuanhui Shi,1 Yuwei Wang,1 Yanlang Yang,1 Wenjun Guo,2,4 Cuifeng Zhang,2 Wenjun Pei,5 and Cong Fu2,3,6

1Department of Nephrology, Yijishan Hospital Affiliated to Wannan Medical College, Wuhu, China
2Anesthesia Laboratory and Training Center of Wannan Medical College, Wuhu, China
3Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution (Wannan Medical College), Wuhu, China
4Department of Anesthesiology, Yijishan Hospital Affiliated to Wannan Medical College, Wuhu, China
5Anhui Province Key Laboratory of Biological Macromolecules Research (Wan Nan Medical College), Wuhu, China
6Department of Cardiology, Yijishan Hospital Affiliated to Wannan Medical College, Wuhu, China

Correspondence should be addressed to Cong Fu; fucong7706@163.com

Received 9 December 2021; Revised 28 January 2022; Accepted 4 February 2022; Published 18 February 2022

Academic Editor: Wen-Qing Shi

Copyright © 2022 Yuhan Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

At present, there is no noninvasive biomarker of renal fibrosis. The potential diagnostic value of urinary exosome-derived circRNAs from glomerular disease patients for renal fibrosis is still uncertain. Here, we first detected the expression of hsa_circ_0008925 in TGF-β1-cultured HK-2 cell-derived exosomes. Secondly, we collected urine samples from 95 biopsy-proven glomerular disease patients and 34 healthy controls. The expression of hsa_circ_0008925 was analyzed, and the correlation with renal function and pathological changes was calculated. The receiver operating characteristic (ROC) curve for the diagnosis of renal fibrosis was performed. The results showed that in exosomes derived from TGF-β1-cultured HK-2 cells, the expression of hsa_circ_0008925 was increased compared with normal cultured. Further, the expression level of hsa_circ_0008925 was increased in urinary exosomes from renal fibrosis patients and correlated with serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate, and cystatin C. The level of hsa_circ_0008925 was furthermore correlated with the score of tubulointerstitial fibrosis (TIF) and the score of glomerular sclerosis. The ROC curve showed that hsa_circ_0008925 can diagnose renal fibrosis at a cut-off value of 0.093 with a sensitivity of 52.2% and specificity of 96.4%. In summary, we indicated that urinary exosomal hsa_circ_0008925 could be acted as a noninvasive biomarker for renal fibrosis in glomerular diseases patients.

1. Introduction

Chronic kidney disease (CKD) is a major medical problem in China and around the world. A cross-sectional survey revealed that the morbidity of CKD in China is 10.8% [1]. Glomerular disease is a common type of CKD. Glomerular disease includes many pathological types. Renal fibrosis (RF) which is defined as glomerulosclerosis and tubulointerstitial fibrosis (TIF) is a common outcome of all pathological types [2]. RF is a typical manifestation of end-stage renal disease. Renal biopsy is the golden standard for the diagnosis of renal fibrosis. Renal biopsy is a risky procedure that cannot be used as a routine examination in glomerular disease patients. Previous studies have found that urine-containing molecules have the potential to serve as noninvasive biomarkers for RF [3, 4]. So far, there is still no method for the noninvasive and dynamic detection of RF that can be applied in clinical practice.

The biological information contained in urine as well as urinary exosomes has great potential to become biomarkers for glomerular disease and renal fibrosis. Real-time quantitative polymerase chain reaction- (qPCR-) based urinary RNA detection has been found as a novel method for detection of biomarkers of kidney disease [5, 6]. Recently, noncoding
RNA such as circRNAs showed great aptitude as biomarkers of kidney disease progression [7–9]. Urine also contained exosomes [10]. And exosomes contained proteins and RNA, from the cytoplasm of the cells [11, 12]. Urinary exosome secretion and their content, especially mRNAs, miRNAs, and circRNAs, were considered the potential candidates for novel biomarkers of kidney disease. Recently, sec63 has been found correlated with renal interstitial inflammation [13]. sec is the symbol of hsa_circ_0008925. However, it is still uncertain if urinary exosomal circRNAs, especially has_circ_0008925, have the potential to act as renal fibrosis biomarkers. In this study, we aimed to identify the potential candidate biomarkers of RF through the detection of urinary exosomes and further explore the relationship of urinary exosomal has_circ_0008925 with histological changes in glomerular disease patients with RF.

2. Methods

2.1. Cell Culture and Treatment. To determine if TGF-β1-treated HK-2 cell could secrete exosomal has_circ_0008925, HK-2 cells were cultured with Dulbecco’s modified Eagle medium (DMEM)/F12 medium (Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 U/mL penicillin (Gibco), and 100 μg/mL streptomycin (Gibco, USA) in a humidified incubator with 5% CO₂ at 37°C. HK-2 cells were purchased from the National Collection of Authenticated Cell Cultures (Shanghai). The 1×10⁵ HK-2 cells were exposed to 100 ng/mL recombinant TGF-β1 protein (Sino Biological, China) for 24 and 48 hours. The cell supernatants were collected. After centrifugation in 300 g at 4°C for 10 min, the supernatants were collected and further centrifuged in 2000 g at 4°C for 20 min. Then, the supernatants were collected and centrifuged in 100000 g at 4°C for 70 min. The precipitates were collected as exosomes.

2.2. Exosomes from Cell Supernatants Identification. The exosomes from cell supernatants were identified by transmission electron microscope. In brief, a 10 μL exosome sample was dropped on the copper net for precipitation for 1 min, and the filter paper absorbs the floating liquid. Then uranyl acetate 10 μL is added to the copper net for precipitation for 1 min, and the floating liquid is absorbed by the filter paper and dried at room temperature for several minutes. The exosomes were imaged by transmission electron microscope (TEM, Hitachi, HT-7700) at 100 kV. Nanoparticle tracking analysis (NTA) (Particle Metrix, ZetaView) was performed to confirm the particle size. Isolated exosome
Figure 2: Urine-derived exosomes from healthy control and patients’ identification. (a) TEM image of exosomes. (b) NTA analysis of exosomes. (c) Western blot showed that urinary exosomes expressed CD9 and TSG101. Histogram showed that the fold change of CD9 and TSG101 protein expression was normalized to β-actin (*P > 0.05 vs. control).

| Table 1: Clinical characteristics of glomerular disease patients and healthy controls. |
|---------------------------------------------------------------|
| **Glomerular disease (n = 95)** | **Control (n = 34)** | **P value** |
| Age (years) | 44.5 ± 14.6 | 43.6 ± 15.5 | 0.756 |
| Gender (male/female) | 51/44 | 25/9 | 0.067 |
| 24 h proteinuria (g/day) | 2.190 (0.080-21.580) | / | / |
| Scr (mmol/L) | 107.9 ± 92.0 | 62.3 ± 7.0 | 0.005 |
| BUN (mmol/L) | 7.1 ± 4.1 | 4.4 ± 1.1 | <0.001 |
| Cystatin C (mg/L) | 1.39 ± 0.86 | 0.67 ± 0.10 | <0.001 |
| eGFR (mL/min per 1.73 m²) | 84.1 ± 36.0 | 121.0 ± 22.8 | <0.001 |
| Score of TIF | 30 (0-91) | / | / |
| Score of glomerular sclerosis | 1.0 (0-4.0) | / | / |
| Exosomal hsa_circ_0008925 | 0.085 (0.035-0.511) | 0.058 (0.033-0.093) | 0.001 |

Abbreviations: Scr: serum creatinine; eGFR: estimated glomerular filtration rate; BUN: blood urea nitrogen.
samples were appropriately diluted using PBS to measure the particle size and concentration. NTA measurement was recorded and analyzed at 11 positions. The ZetaView system was calibrated using 110 nm polystyrene particles. Temperature was maintained around 23°C and 30°C. Western blot was performed to confirm the expression of exosomes specific marker CD9 and TSG101 using rabbit CD9 antibody, rabbit TSG101 antibody (ProteinTech, USA) and HRP-labeled goat anti-rabbit IgG (H+L) (Beyotime, China). β-Actin was used as a loading control (Biosharp, China).

2.3. Detection of hsa_circ_0008925 in Exosomes from Cell Supernatants. The whole RNA in exosomes was isolated using TRIzol-LS (Invitrogen, USA) according to the manufacturer’s protocol. The concentration and purity of RNA were assessed using the relative absorbance ratio at 260/280 in a NanoDrop 2000 (Thermo, USA). The reverse transcription was performed using THE PrimeScript™ RT Reagent Kit (TAKARA, Japan) according to the manufacturer’s protocol. RT-PCR was performed using the TB Green Premix Ex Taq Kit (TAKARA, Japan). The primers was as follows: hsa_circ_0008925 primers (sense: 5′-TTATGGCTGTCCTTGGGAGTTT-3′; antisense: 5′-GGTATTCTCGGTCTGTTTGGA-3′) and U6 primers (sense: 5′-GCTTCGACACCAATCATCTAAAT-3′; antisense: 5′-CGCTTCACGAAAATTGCGTGTCAT-3′). The hsa_circ_0008925 expression was normalized to U6 and calculated as $2^{-\Delta\Delta C_T}$.

2.4. Study Population. To determine if urinary exosomes displayed a high-level expression of hsa_circ_0008925 in glomerular disease patients, a total of 95 biopsy-proven glomerular disease patients were selected from the Department of Nephrology, Yijishan Hospital, Wannan Medical College. The pathological types of 95 glomerular disease patients concluded IgA nephropathy ($n=34$), membranous nephropathy ($n=27$), minimal-change glomerulonephritis ($n=16$), focal segmental glomerulosclerosis ($n=2$), diabetic

---

**Figure 3**: hsa_circ_0008925 expression in urinary exosomes from glomerular disease patients and healthy control. (a) Expression of hsa_circ_0008925 was significantly increased in glomerular disease patients compared to healthy controls. (b) In glomerular disease patients, urinary exosome hsa_circ_0008925 expression was significantly increased in mild-moderate and severe renal fibrosis patients compared to no fibrosis ($^*P<0.001$ vs. control; $^{**}P=0.002$ vs. no fibrosis; $^{***}P=0.0038$ vs. mild-moderate).

**Table 2**: Clinical and pathological characteristics of glomerular disease patients.

|                            | None ($n=28$) | Mild-moderate ($n=39$) | Severe ($n=28$) | $P$ value |
|-----------------------------|---------------|------------------------|----------------|-----------|
| Age (y)                     | 42.9±18.2     | 41.7±12.2              | 49.9±12.6      | 0.061     |
| Sex (M/F)                   | 11/17         | 21/18                  | 19/9           | 0.100     |
| Scr (μmol/L)                | 83.5±37.1     | 88.6±73.0              | 159.2±129.4    | 0.002     |
| BUN (mmol/L)                | 7.1±4.2       | 5.6±3.0                | 9.1±4.7        | 0.002     |
| Cystatin C (mg/L)           | 1.19±0.63     | 1.06±0.54              | 2.05±1.07      | <0.001    |
| eGFR (mL/min per 1.73 m²)   | 94.2±35.8     | 98.6±31.1              | 54.0±22.8      | <0.001    |
| 24 h proteinuria (g/day)    | 2.130 (0.080-9.160) | 1.290 (0.100-21.580)  | 2.810 (0.220-13.210) | 0.227 |
| hsa_circ_0008925            | 0.055 (0.035-0.095) | 0.086 (0.051-0.125)  | 0.098 (0.050-0.512) | <0.001 |
| Score of TIF (%)            | 0             | 30 (10-45)             | 70 (52-91)     | <0.001    |
| Score of glomerular sclerosis | 0.6 (0-1.0) | 1.0 (0-2.4)           | 2.3 (1.0-4.0)  | <0.001    |

Abbreviations: Scr: serum creatinine; eGFR: estimated glomerular filtration rate; BUN: blood urea nitrogen.
nephropathy (n = 3), hypertensive nephropathy (n = 4), intracapillary proliferative glomerulonephritis (n = 1), mesangial proliferative glomerulonephritis (n = 3), membra-
 noproliferative glomerulonephritis (n = 1), crescentic glo-
 merulonephritis (n = 2), and lupus nephritis (n = 2). The
 exclusion criteria were as follows: patients younger than 18
 years old or older than 80 years old; patients with chronic
 liver disease, urinary tract infection, cancer, or organ trans-
 plantation; glomerular disease patients with severe complica-
 tions: cardiovascular disorder; or the use of steroids or
 immunosuppressive medications. The results of the labora-
 tory examination were collected. Age- and gender-matched
 healthy volunteers (n = 54) also enrolled who were de-
 fined with the absence of abnormalities on a routine urinalysis
 and normal renal function (estimated glomerular
 filtration rate (eGFR) > 90 mL min/1.73 m²).

2.5. Collection of Urine Samples and Exosomes. The whole-
 stream early-morning urine specimens were collected after
 hospitalization. 100 mL urine sample was centrifuged at
 3000 g for 30 min at 4°C. Then, the supernatants were centri-
 fuged at 13500 g for 30 min at 4°C. The sediments were dis-
 carded, and the supernatants were centrifuged at 100000 g
 for 70 min at 4°C. The sediments were suspended in 100 μL
 phosphate buffer saline (PBS) as urinary exosomes. Exo-
 somes were identiﬁed as described above.

2.6. Detection of hsa_circ_0008925 in Urinary Exosomes. The
 RNA from exosomes was isolated as described above. The
 reverse transcription and RT-PCR were performed as
described above.

2.7. Assessment of Renal Fibrosis. Analysis of renal fibrosis
 was performed on paraffin-embedded sections stained with
 periodic acid-Schiff and Masson trichrome. Serial 3 μm sec-
tions were acquired from each paraffin block. Two experi-
cenced pathologists who were blinded to the results of
 molecular studies subjectively scored the severity of renal

Figure 4: Correlation between urinary exosomal hsa_circ_0008925 expression and kidney function. (a) Spearman’s correlation between hsa_circ_0008925 and Scr ($r_s = 0.348, P < 0.001$). (b) Spearman’s correlation between hsa_circ_0008925 and BUN ($r_s = 0.247, P = 0.005$). (c) Spearman’s correlation between hsa_circ_0008925 and cystatin C ($r_s = 0.442, P < 0.001$). (d) Spearman’s correlation between hsa_circ_0008925 and eGFR ($r_s = -0.267, P = 0.002$).
fibrosis. The degree of renal fibrosis for glomerular disease patients was evaluated, and the score of TIF and glomerular sclerosis performed on Masson-stained sections was calculated according to the previous study [3]. No fibrosis was considered 0 of the renal interstitium fibrosis. Mild-moderate fibrosis was considered ≤50%. Severe was considered >50%

### 2.8. Western Blot

The protein in exosomes from cell supernatants and urine were collected using RIPA lysis buffer (Beyotime, China). Protein concentration was determined using a BCA kit (Beyotime, China). The CD9 and TSG101 protein expressions were determined by western blot. Rabbit anti-human CD9 antibody (ProteinTech, USA) and rabbit anti-human TSG101 antibody (ProteinTech, USA) were used. HRP-labeled goat anti-rabbit IgG (Beyotime, China) was used as the secondary antibody. β-Actin was used as a loading control (Biosharp, China).

### 2.9. Statistical Analysis

SPSS 17.0 was used for data analysis. The method of calculating the relative expression of circRNA was described in the previous study. Statistical comparison of different types of data, the correlation coefficient, logistic regression, and receiver operating characteristic (ROC) curves were calculated according to a previous study described [3]. Relative changes in gene expression were calculated using the ΔΔCt (threshold cycle) method: ΔCt = Ct gene of interest – Ct internal control, while ΔΔCt = ΔCt gene of interest – ΔCt internal control sample – Ct gene of interest

---

**Figure 5:** Correlation between urinary exosomal hsa_circ_0008925 expression and 24 h proteinuria, renal fibrosis pathological score. (a) Spearman’s correlation between hsa_circ_0008925 and 24 h proteinuria ($r_s = -0.055$, $P = 0.599$). (b) Spearman’s correlation between hsa_circ_0008925 and the score of TIF ($r_s = 0.506$, $P < 0.001$). (c) Spearman’s correlation between hsa_circ_0008925 and the score of glomerular sclerosis ($r_s = 0.354$, $P < 0.001$).

### Table 3: Multivariate logistic regression analysis of selected variables for renal fibrosis.

| OR     | 95% CI          | P value |
|--------|-----------------|---------|
| hsa_circ_0008925 | 1.517 1.178-1.954 | 0.001  |
| Scr    | 1.027 0.993-1.063 | 0.116  |
| BUN    | 0.800 0.611-1.046 | 0.103  |
| Cystatin C | 0.660 0.104-4.189 | 0.660  |
| eGFR   | 0.996 0.969-1.024 | 0.784  |
| 24 h proteinuria | 1.093 0.889-1.343 | 0.400  |

Abbreviations: Scr: serum creatinine; eGFR: estimated glomerular filtration rate; BUN: blood urea nitrogen; OR: odds ratio; CI: confidence interval.
3. Results

3.1. Elevated Expression of hsa_circ_0008925 in Cell Supernatant-Derived Exosomes. To identify the change of exosome release in TGF-β1-treated HK-2 cell, we isolated, characterized, and quantified exosomes from cell supernatants using transmission electron microscopy (TEM), western blotting (using CD9 and TSG101 as exosome markers), and ZetaView nanoparticle tracking analysis (NTA). Figure 1(a) showed the TEM image of exosomes. The NTA is shown in Figure 1(b). Exosomes purified from cell culture supernatants showed the typical size and shape. The western blot exhibited that exosomes expressed specific protein markers CD9 and TSG101 compared to HK-2 cells (Figure 1(c)). RT-PCR showed that after coculture with 100 ng/mL TGF-β1 for 24 h and 48 h, the hsa_circ_0008925 expression in cell-derived exosomes was significantly increased compared to normal cultured (Figure 1(d)).

3.2. Identification of Urinary Exosomes from Healthy and Glomerular Disease Patients. The TEM images and ZetaView nanoparticle tracking analysis of urinary exosomes are shown in Figure 2. Exosomes purified from urine exhibited the typical size and shape. The western blot of CD9 and TSG101 (Figure 2(c)) identified that exosomes expressed specific protein markers CD9 and TSG101.

3.3. Baseline Characters of Patients. The clinical characters of the involved subjects are shown in Table 1. There were no significant differences in age and gender between glomerular disease patients and controls. The glomerular disease patients showed high levels of Scr, BUN, and cystatin C and low estimated glomerular filtration rate (eGFR) compared with controls. eGFR was calculated by modified MDRD equations [14]. The relative expression level of hsa_circ_0008925 was significantly increased in the glomerular disease patients (median expression 0.085 in glomerular disease vs. 0.058 in healthy controls, P < 0.001 vs. control, Figure 3(a)).

The 95 glomerular disease patients included 28 patients without renal fibrosis, 39 patients with mild-moderate renal fibrosis, and 28 patients with severe renal fibrosis. As shown in Table 2, there were no significant differences in age, gender, and 24 h proteinuria among these 3 groups. The relative expression level of urinary exosomal hsa_circ_0008925 was significantly higher in the mild-moderate group and severe group compared to the no fibrosis group (Median expression 0.086 in mild-moderate vs. 0.055 in the no fibrosis group, P = 0.002; mild-moderate vs. 0.098 in severe, P = 0.038; Figure 3(b)).

3.4. Correlation between Urinary Exosomal hsa_circ_0008925 and Clinical Parameters as well as Pathological Parameters. Urinary exosomal hsa_circ_0008925 correlated with Scr (r_s = 0.348, P < 0.001), BUN (r_s = -0.215, P = 0.005), cystatin C (r_s = 0.442, P < 0.001), and eGFR (r_s = -0.267, P = 0.002; Figure 4). In glomerular disease patients, urinary exosomal hsa_circ_0008925 correlated with the score of TIF (r_s = 0.506, P < 0.001) and the score of glomerular sclerosis (r_s = 0.354, P < 0.001; Figure 5). However, urinary exosomal hsa_circ_0008925 did not correlate with 24 h proteinuria (r_s = -0.055, P = 0.599).

The stepwise multivariate logistic regression analysis further showed that the relative expression of urinary exosomal hsa_circ_0008925 significantly correlated with renal fibrosis (Table 3, OR: 1.517; 95% CI: 1.178-1.954; P < 0.001). In addition, Scr, BUN, cystatin C, eGFR, and 24 h proteinuria had no statistical significance in the correlation with renal fibrosis by the stepwise multivariable logistic regression analysis (Table 3).

3.5. Diagnostic Value of Urinary Exosomal hsa_circ_0008925 for Renal Fibrosis. The results showed that urinary exosomal hsa_circ_0008925 could effectively distinguish renal fibrosis from no fibrosis, with the largest AUC of 0.782 (95% CI: 0.690-0.874; P < 0.001) higher than that of Scr (AUC of 0.625; 95% CI: 0.504-0.760; P = 0.055), BUN (AUC of 0.479; 95% CI: 0.351-0.606; P = 0.744), cystatin C (AUC of...
of tubular epithelial cells and excessive accumulation of the extracellular matrix are important factors which may influence renal fibrosis [22, 23]. There are a few studies on whether circular RNA in tubular epithelial cells is involved in renal fibrosis. Peng et al. found that the circRNA_010383 expression level was markedly downregulated in tubular epithelial cells cultured in high-glucose conditions. Loss of circRNA_010383 promoted proteinuria and renal fibrosis in DN by acting as a sponge for miRNA-135a [24]. Wen et al. reported that circACTR2 regulated high glucose-induced pyroptosis, inflammation, and fibrosis in proximal tubular cells, circACTR2 was defined as a novel circular RNA-regulated high glucose-induced fibrosis [25]. Cui et al. revealed that circZNF609 is involved in the pathogenesis of focal segmental glomerulosclerosis [26]. Xu et al. further found that circEIF4G2 aggravates renal fibrosis in mouse models and rat cell lines [27]. These researches indicated that in CKD that progressed to renal fibrosis, circular RNAs played a key role in the progression of the disease. In our research, we first suggested that the expression level of hsa_circ_0008925 increased in TGF-β1-cultured HK-2 cell-derived exosomes. The elevated level of hsa_circ_0008925 in urinary exosomes was probably from tubular epithelial cells. So far, there was no relevant research that revealed the biological function of hsa_circ_0008925. hsa_circ_0008925 originated from chr6:108222573-108246136, and the gene symbol was sec63. Ishikawa et al. found that the loss of sec63 promoted spliced XBP1 which alleviated renal interstitial inflammation [13]. In this study, our data strongly suggested that hsa_circ_0008925 participated in the progression of renal fibrosis and indicated that hsa_circ_0008925 might be used as a noninvasive biomarker of renal fibrosis.

Our study also has some limitations. First, this study did not focus on the specific pathological types of glomerular disease. Whether the urinary exosomal hsa_circ_0008925 can be used as renal fibrosis biomarkers in different pathological types still needs to be further determined by large sample size research. Second, subsequent cell and animal studies are needed in the future research to determine the mechanism of hsa_circ_0008925 in renal fibrosis. Additionally, whether hsa_circ_0008925 will affect the prognosis of patients with renal fibrosis is uncertain and still needs to be further studied.

5. Conclusion

Patients with renal fibrosis showed a higher urinary exosomal hsa_circ_0008925 expression level than patients with no fibrosis, which suggested the potential of urinary exosomal hsa_circ_0008925 to become a noninvasive biomarker for renal fibrosis.

Data Availability

The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

4. Discussion

In this study, we found that tubular epithelial cell-derived exosomes contained a high level of hsa_circ_0008925 in the renal fibrosis model in vitro. In addition, we found that the urinary exosomal hsa_circ_0008925 expression level was increased in glomerular disease patients. Furthermore, within glomerular disease patients, patients with renal fibrosis showed a higher urinary exosomal hsa_circ_0008925 expression level than patients with no fibrosis, which suggested the potential of urinary exosomal hsa_circ_0008925 to become a noninvasive biomarker for renal fibrosis.

Noninvasive and repeatable detection of renal fibrosis is the key for early monitoring and prevention of glomerular disease progression. Additionally, biomarkers often play an important role in the occurrence and development of diseases and are major molecules to reveal the pathogenesis of diseases. However, renal biopsy is incapable of the advantages of being noninvasive and repeatable. Noninvasive markers and detection methods of renal fibrosis are necessary in clinical practice. In 2001, Li et al. first established a noninvasive approach to diagnose acute renal rejection of allografts by isolating and quantifying RNA of specific genes in urine sediments [5]. Subsequently, many studies found that the RNA contained in urinary sediment cells is related to a variety of kidney diseases and has the application value of biomarkers [3, 14–17]. Urinary sediment contains different types of cells, including renal intrinsic cells. The difference in mRNA expression in urinary sediment cannot accurately reflect the state of renal disease.

Pisitkun et al. first found exosomes in urine [10]. Urine exosomes are produced by the fusion of MV with renal epithelial cells which can reflect the pathological changes of the kidney [18]. Previous studies have found that protein, mRNA, and miRNA in urinary exosomes can be used as biomarkers for the diagnosis of CKD [4, 19, 20]. Exosomes contained abundant circRNAs [21]. Ma et al. reported that 89 circRNAs were significantly differentially expressed in idiopathic membranous nephropathy patients’ urine exosomes and MUC3A could be considered a potential diagnostic biomarker of idiopathic membranous nephropathy [9]. In our study, we found that HK-2 cell-derived exosomes contained a high level of hsa_circ_0008925 in the fibrotic microenvironment in vitro. That strongly indicated that in renal fibrosis, renal tubular epithelial cells secrete a large number of circRNAs carried by exosomes. Urinary exosomal hsa_circ_0008925 expression level correlated with renal function and pathological changes, which may show the potential of the ability to diagnose renal fibrosis.

Tubular epithelial cells play an important role in renal fibrosis. A previous study showed that the metabolic state of tubular epithelial cells and excessive accumulation of the
Ethical Approval
The Ethical Committee of Yijishan Hospital, Wannan Medical College, approved all studies (approval number: 2017LSY No.18).

Consent
Written informed consents were obtained from all subjects. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Disclosure
The sponsors played no role in the preparation of data or the manuscript.

Conflicts of Interest
The authors have no conflicts of interest to declare.

Authors’ Contributions
Yuhan Cao and Yuanhui Shi contributed equally to this work.

Acknowledgments
This research is financially supported by the National Natural Science Foundation of China (81702092 to Yuhan Cao, 81700265 to Cong Fu).

References
[1] L. Zhang, F. Wang, L. Wang et al., “Prevalence of chronic kidney disease in China: a cross-sectional survey,” Lancet, vol. 379, no. 9818, pp. 815–822, 2012.
[2] Y. Liu, “Cellular and molecular mechanisms of renal fibrosis,” Nature Reviews. Nephrology, vol. 7, no. 12, pp. 684–696, 2011.
[3] Y. Cao, Y. Wang, N. Peng, J. Xiao, S. Wang, and C. Fu, “The ratio of urinary TREM-1/TREM-2 mRNA expression in chronic kidney disease and renal fibrosis,” Annals of Medicine, vol. 53, no. 1, pp. 1010–1018, 2021.
[4] Y. Feng, L. L. Lv, W. J. Wu et al., “Urinary exosomes and exosomal CCL2 mRNA as biomarkers of active histologic injury in IgA nephropathy,” The American Journal of Pathology, vol. 188, no. 11, pp. 2542–2552, 2018.
[5] B. Li, C. Hartono, R. Ding et al., “Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine,” The New England Journal of Medicine, vol. 344, pp. 947–954, 2001.
[6] M. Suthanthiran and T. Muthukumar, “Urinary-cell mRNA and acute kidney-transplant rejection,” The New England Journal of Medicine, vol. 369, pp. 1860–1861, 2013.
[7] J. Jin, H. Sun, C. Shi et al., “Circular RNA in renal diseases,” Journal of Cellular and Molecular Medicine, vol. 24, no. 12, pp. 6523–6533, 2020.
[8] M. Kölling, H. Seeger, G. Haddad et al., “The circular RNA cirs-126 predicts survival in critically ill patients with acute kidney injury,” Kidney International Reports, vol. 3, no. 5, pp. 1144–1152, 2018.
[9] H. Ma, Y. Xu, R. Zhang, B. Guo, S. Zhang, and X. Zhang, “Differential expression study of circular RNAs in exosomes from serum and urine in patients with idiopathic membranous nephropathy,” Archives of Medical Science, vol. 15, no. 3, pp. 738–753, 2019.
[10] T. Pisitkun, R. F. Shen, and M. A. Knepper, “Identification and proteomic profiling of exosomes in human urine,” Proceedings of the National Academy of Sciences, vol. 101, no. 36, pp. 13368–13373, 2004.
[11] C. Théry, L. Zitvogel, and S. Amigorena, “Exosomes: composition, biogenesis and function,” Nature Reviews. Immunology, vol. 2, no. 8, pp. 569–579, 2002.
[12] A. V. Vlassov, S. Magdaleno, R. Setterquist, and R. Conrad, “Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials,” Biochimica et Biophysica Acta, vol. 1820, no. 7, pp. 940–948, 2012.
[13] Y. Ishikawa, S. Fedeles, A. Marlier et al., “Spliced XBPI rescues renal interstitial inflammation due to loss of sc63 in collecting ducts,” Journal of the American Society of Nephrology, vol. 30, no. 3, pp. 443–459, 2019.
[14] Y. H. Cao, L. L. Lv, X. Zhang et al., “Urinary vimentin mRNA as a potential novel biomarker of renal fibrosis,” American Journal of Physiology. Renal Physiology, vol. 309, pp. F514–F522, 2015.
[15] Y. Cao, Y. Wang, Y. Liu et al., “Decreased expression of urinary mammalian target of rapamycin mRNA is related to chronic renal fibrosis in IgAN,” Disease Markers, vol. 2019, Article ID 2424751, 10 pages, 2019.
[16] M. Zheng, L. L. Lv, Y. H. Cao et al., “Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy,” Clinical Endocrinology, vol. 76, pp. 657–664, 2012.
[17] M. Zheng, L. L. Lv, J. Ni et al., “Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy,” PLoS One, vol. 6, article e20431, 2011.
[18] P. Gonzales, T. Pisitkun, and M. A. Knepper, “Urinary exosomes: is there a future?,” Nephrology, Dialysis, Transplantation, vol. 23, no. 6, pp. 1799–1801, 2008.
[19] P. G. Moon, J. E. Lee, S. You et al., “Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy,” Proteomics, vol. 11, no. 12, pp. 2459–2475, 2011.
[20] T. Chen, C. Wang, H. Yu et al., “Increased urinary exosomal microRNAs in children with idiopathic nephrotic syndrome,” eBioMedicine, vol. 39, pp. 552–561, 2019.
[21] Y. Li, Q. Zheng, C. Bao et al., “Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis,” Cell Research, vol. 25, no. 8, pp. 981–984, 2015.
[22] H. M. Kang, S. H. Ahn, P. Choi et al., “Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development,” Nature Medicine, vol. 21, no. 1, pp. 37–46, 2015.
[23] L. Zhang, L. Liu, M. Bai et al., “Hypoxia-induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF-xB,” The FASEB Journal, vol. 34, no. 2, pp. 2554–2567, 2020.
[24] F. Peng, W. Gong, S. Li et al., “circRNA_010383 acts as a sponge for miR-135a and its downregulated expression contributes to renal fibrosis in diabetic nephropathy,” Diabetes, vol. 70, no. 2, pp. 603–615, 2020.
[25] S. Wen, S. Li, L. Li, and Q. Fan, “circACTR2: a novel mechanism regulating high glucose-induced fibrosis in renal tubular cells via pyroptosis,” *Biological & Pharmaceutical Bulletin*, vol. 43, no. 3, pp. 558–564, 2020.

[26] X. Cui, J. Fu, J. Luan et al., “Circ ZNF609 is involved in the pathogenesis of focal segmental glomerulosclerosis by sponging miR-615-5p,” *Biochemical and Biophysical Research Communications*, vol. 531, no. 3, pp. 341–349, 2020.

[27] B. Xu, Q. Wang, W. Li et al., “Circular RNA circEIF4G2 aggravates renal fibrosis in diabetic nephropathy by sponging miR-218,” *Journal of Cellular and Molecular Medicine*, 2020.